Humacyte, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $753,000, a significant increase from zero revenue in the same period last year. This revenue was primarily driven by product sales of its FDA-approved product, Symvess, which generated $703,000 in product revenue, alongside $50,000 from contract revenue. The company’s operating expenses for the quarter were $25.1 million, down from $30.2 million in the prior year, reflecting a 17% decrease. The reduction in expenses was attributed to lower research and development costs, which fell by 25% to $17.3 million, as the company capitalized on overhead costs associated with the commercial manufacturing of Symvess.
In terms of profitability, Humacyte reported a net loss of $17.5 million for the quarter, a 55% improvement compared to a net loss of $39.2 million in the same quarter of 2024. The company’s total operating loss was $24.4 million, down from $30.2 million year-over-year. The decrease in losses was supported by a notable increase in other income, primarily from a $4.9 million gain related to the fair value remeasurement of the Contingent Earnout Liability, which contrasted sharply with a loss in the previous year.
Operationally, Humacyte has made strides in its product development and commercialization efforts. The company has successfully launched Symvess in the U.S. market and is actively pursuing additional indications for its acellular tissue engineered vessels (ATEVs). As of September 30, 2025, the company had cash and cash equivalents of $19.5 million, down from $44.9 million at the end of 2024, reflecting ongoing investments in research and development and commercial activities. The company also reported an accumulated deficit of $702 million, indicating the financial challenges it continues to face as it scales its operations.
Strategically, Humacyte has entered into a Revenue Interest Purchase Agreement to secure financing for the development and commercialization of its ATEVs. As of September 30, 2025, the company had a revenue interest liability of $20.7 million, down from $64.2 million at the end of 2024, following a $50 million repayment made in connection with an amendment to the agreement. The company has also implemented cost-saving measures, including a workforce reduction of 30 employees, aimed at improving its cash runway and aligning its organizational structure with business objectives.
Looking ahead, Humacyte anticipates continued operating losses as it focuses on expanding its product offerings and market presence. The company plans to leverage its existing cash reserves and financing agreements to support its operations for at least the next twelve months. However, it acknowledges the need for additional capital to fund ongoing research and development, as well as commercialization efforts for Symvess and other product candidates. The company remains committed to advancing its innovative technology platform while navigating the complexities of the biotechnology market.
About Humacyte, Inc.
Humacyte, Inc. develops bioengineered human tissues and acellular vascular grafts for medical use. Its core products include the FDA-approved Symvess ATEV for vascular repair, reconstruction, and replacement, targeting trauma, dialysis access, PAD, and cardiac surgery markets. The company leverages scalable manufacturing and proprietary technology to produce off-the-shelf, universally implantable tissues with low infection and rejection rates, aiming to improve patient outcomes and transform regenerative medicine.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.